{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:08:47Z","timestamp":1788786527370,"version":"build-2803163510"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography A"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.chroma.2026.467288","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T14:50:11Z","timestamp":1784645411000},"page":"467288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application"],"prefix":"10.1016","volume":"1786","author":[{"given":"Lok-Hang","family":"Tong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"King-Kwong","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Tat","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chroma.2026.467288_bib0001","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41392-024-02107-5","article-title":"Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines","volume":"10","author":"Xiao","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.chroma.2026.467288_bib0002","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.tips.2023.04.003","article-title":"Recent advances in the development of therapeutic peptides","volume":"44","author":"Fetse","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.chroma.2026.467288_bib0003","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic peptides: current applications and future directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.chroma.2026.467288_bib0004","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s12276-023-01016-x","article-title":"Peptides as multifunctional players in cancer therapy","volume":"55","author":"Vadevoo","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.chroma.2026.467288_bib0005","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00011-018-1208-x","article-title":"Antiinflammatory peptides: current knowledge and promising prospects","volume":"68","author":"Dadar","year":"2019","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.chroma.2026.467288_bib0006","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1007\/s00018-019-03138-w","article-title":"Antiviral peptides as promising therapeutic drugs","volume":"76","author":"Vilas Boas","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.chroma.2026.467288_bib0007","article-title":"FDA's stamp of approval: unveiling peptide breakthroughs in cardiovascular diseases, ACE, HIV, CNS, and beyond","volume":"30","author":"Al Musaimi","year":"2024","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.chroma.2026.467288_bib0008","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.chroma.2026.467288_bib0009","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.chroma.2026.467288_bib0010","doi-asserted-by":"crossref","DOI":"10.1124\/pharmrev.123.001045","article-title":"Emerging pharmacotherapies for obesity: a systematic review","volume":"77","author":"Kokkorakis","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.chroma.2026.467288_bib0011","first-page":"1358","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"29","author":"Ussher","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.chroma.2026.467288_bib0012","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2023.2292461","article-title":"Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"12","author":"Rhea","year":"2024","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.chroma.2026.467288_bib0013","doi-asserted-by":"crossref","DOI":"10.1172\/JCI194751","article-title":"Antiinflammatory actions of glucagon-like peptide-1\u2013based therapies beyond metabolic benefits","volume":"135","author":"Wong","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.chroma.2026.467288_bib0014","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41591-025-04124-5","article-title":"The expanding landscape of GLP-1 medicines","volume":"32","author":"Drucker","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.chroma.2026.467288_bib0015","doi-asserted-by":"crossref","DOI":"10.1124\/pharmrev.123.001045","article-title":"Emerging pharmacotherapies for obesity: a systematic review","volume":"77","author":"Kokkorakis","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.chroma.2026.467288_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fcdhc.2025.1590530","article-title":"Exploring the multifaceted roles of GLP-1 receptor agonists; a comprehensive review","volume":"6","author":"Hammad","year":"2025","journal-title":"Front. Clin. Diabetes Healthc."},{"key":"10.1016\/j.chroma.2026.467288_bib0017","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.chroma.2026.467288_bib0018","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jpha.2019.02.001","article-title":"Comparison of ELISA and HPLC-MS methods for the determination of exenatide in biological and biotechnology-based formulation matrices","volume":"9","author":"Pinho","year":"2019","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.chroma.2026.467288_bib0019","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s13361-015-1231-x","article-title":"Limitations of mass spectrometry-based peptidomic approaches","volume":"26","author":"Fricker","year":"2015","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.chroma.2026.467288_bib0020","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1021\/jasms.5c00105","article-title":"Absolute quantitation of coeluting impurities in peptide drugs using high resolution mass spectrometry: glucagon a case study in pharmaceutical development","volume":"36","author":"Kodidasu","year":"2025","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.chroma.2026.467288_bib0021","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1208\/s12248-015-9730-z","article-title":"Liquid chromatography-high resolution mass spectrometry for peptide drug quality control","volume":"17","author":"Zeng","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.chroma.2026.467288_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.116654","article-title":"Validation of a liquid chromatography-high resolution mass spectrometry method to quantify peptide-related impurities in teriparatide","volume":"255","author":"Weisz","year":"2025","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.chroma.2026.467288_bib0023","doi-asserted-by":"crossref","DOI":"10.1002\/rcm.70030","article-title":"Identification and quantification of structurally related peptide impurity in linaclotide by liquid chromatography-high resolution mass spectrometry","volume":"40","author":"Cheng","year":"2026","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.chroma.2026.467288_bib0024","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2337\/db25-769-P","article-title":"Bofanglutide (GZR18), a novel GLP-1RA, improved glycemic control and cardiometabolic risk factors in Chinese patients with T2D","volume":"74","author":"Li","year":"2025","journal-title":"Diabetes"},{"key":"10.1016\/j.chroma.2026.467288_bib0025","doi-asserted-by":"crossref","first-page":"752","DOI":"10.2337\/db25-752-P","article-title":"Efficacy and safety of bofanglutide (GZR18), a biweekly GLP-1RA, compared with semaglutide in Chinese patients with T2D","volume":"74","author":"Wu","year":"2025","journal-title":"Diabetes"},{"key":"10.1016\/j.chroma.2026.467288_bib0026","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1038\/s41467-025-68165-7","article-title":"Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Zhu","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chroma.2026.467288_bib0027","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S2213-8587(25)00141-X","article-title":"Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Ji","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.chroma.2026.467288_bib0028","article-title":"Exenatide for obesity in children and adolescents: systematic review and meta-analysis","volume":"15","author":"Chen","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.chroma.2026.467288_bib0029","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/14656566.2017.1282463","article-title":"Exenatide: pharmacokinetics, clinical use, and future directions","volume":"18","author":"Knop","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.chroma.2026.467288_bib0030","article-title":"Liraglutide for adults living with obesity","volume":"2025","author":"Meza","year":"2025","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.chroma.2026.467288_bib0031","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.chroma.2026.467288_bib0032","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","article-title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","volume":"30","author":"Ryan","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.chroma.2026.467288_bib0033","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.chroma.2026.467288_bib0034","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa2411528","article-title":"Once-weekly mazdutide in Chinese adults with obesity or overweight","volume":"392","author":"Ji","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.chroma.2026.467288_bib0035","doi-asserted-by":"crossref","first-page":"8289","DOI":"10.1038\/s41467-023-44067-4","article-title":"A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity","volume":"14","author":"Ji","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chroma.2026.467288_bib0036","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","volume":"12","author":"le Roux","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.chroma.2026.467288_bib0037","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/dom.16052","article-title":"Survodutide, a glucagon receptor\/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: a post hoc analysis from a randomized, placebo-controlled, dose-finding, phase 2 trial","volume":"27","author":"le Roux","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.chroma.2026.467288_bib0038","first-page":"224","article-title":"Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review","volume":"21","author":"Forzano","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.chroma.2026.467288_bib0039","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s13300-025-01804-w","article-title":"Insights into the mechanism of action of tirzepatide: a narrative review","volume":"17","author":"Galindo","year":"2026","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.chroma.2026.467288_bib0040","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s12170-025-00770-z","article-title":"Triple agonism based therapies for obesity","volume":"19","author":"Goldney","year":"2025","journal-title":"Curr. Cardiovasc. Risk Rep."},{"key":"10.1016\/j.chroma.2026.467288_bib0041","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3390\/biom15060796","article-title":"Retatrutide\u2014a game changer in obesity pharmacotherapy","volume":"15","author":"Katsi","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.chroma.2026.467288_bib0042","unstructured":"Gan & Lee Pharmaceuticals, Gan & Lee Pharmaceuticals announced first participants dosed in phase 3 clinical study (GRADUAL-2) of bofanglutide (GZR18) injection in Chinese adults with overweight or obesity. https:\/\/www.ganlee.com\/detail\/825.html (Accessed 27 May 2026)."},{"key":"10.1016\/j.chroma.2026.467288_bib0043","unstructured":"National Medical Products Administration, \u56fd\u5bb6\u836f\u76d1\u5c40\u6279\u51c6\u57c3\u8bfa\u683c\u9c81\u80bd\u6ce8\u5c04\u6db2\u4e0a\u5e02 (National Medical Products Administration approves ecnoglutide injection (Xianyida) for marketing). https:\/\/www.nmpa.gov.cn\/directory\/web\/nmpa\/\/zhuanti\/zt2023\/ypgzhlfzh\/shypqxgg\/ggjzcx\/20260130142923121.html (Accessed 27 May 2026)."},{"key":"10.1016\/j.chroma.2026.467288_bib0044","unstructured":"National Medical Products Administration, \u56fd\u5bb6\u836f\u76d1\u5c40\u6279\u51c6\u739b\u4ed5\u5ea6\u80bd\u6ce8\u5c04\u6db2\u4e0a\u5e02 (National Medical Products Administration approves mazdutide injection (Xinerme) for marketing). https:\/\/www.nmpa.gov.cn\/zhuanti\/cxylqx\/cxypxx\/20250627145044169.html (Accessed 27 May 2026)."},{"key":"10.1016\/j.chroma.2026.467288_bib0045","unstructured":"B. Ingelheim, Phase 3 studies survodutide obesity and overweight. https:\/\/www.boehringer-ingelheim.com\/human-health\/metabolic-diseases\/phase-3-studies-survodutide-obesity-and-overweight (Accessed 27 May 2026)."},{"key":"10.1016\/j.chroma.2026.467288_bib0046","unstructured":"Eli Lilly and Company, A study of retatrutide (LY3437943) in participants without type 2 diabetes who have obesity or overweight (TRIUMPH-9). https:\/\/trials.lilly.com\/en-US\/trial\/687735 (Accessed 27 May 2026)."},{"key":"10.1016\/j.chroma.2026.467288_bib0047","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2147\/DMSO.S421527","article-title":"Research advances in fusion protein-based drugs for diabetes treatment","volume":"Volume 17","author":"Deng","year":"2024","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"10.1016\/j.chroma.2026.467288_bib0048","unstructured":"European Medicines Agency. Lyxumia (lixisenatide): withdrawal of the marketing authorisation. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lyxumia (Accessed 27 May 2026)."},{"key":"10.1016\/j.chroma.2026.467288_bib0049","unstructured":"Hangzhou Sciwind Biosciences Co., Ltd., Sciwind Biosciences announces global licensing and collaboration agreement for metabolic disease portfolio. https:\/\/www.prnewswire.com\/news-releases\/sciwind-biosciences-announces-global-licensing-and-collaboration-agreement-for-metabolic-disease-portfolio-302347773.html (Accessed 27 May 2026)."},{"key":"10.1016\/j.chroma.2026.467288_bib0050","article-title":"Alternative mobile phase additives for the characterization of protein biopharmaceuticals by reversed-phase and hydrophilic interaction liquid chromatography","volume":"1177","author":"Lardeux","year":"2021","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.chroma.2026.467288_bib0051","doi-asserted-by":"crossref","first-page":"9962","DOI":"10.3390\/ijms26209962","article-title":"Peptide mapping for sequence confirmation of therapeutic monoclonal antibodies and recombinant vaccine antigens by high-resolution mass spectrometry: software limitations, pitfalls, and lessons learned","volume":"26","author":"Dobrowolski","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.chroma.2026.467288_bib0052","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/j.jasms.2007.09.016","article-title":"MS\/MS of protonated polyproline peptides: the influence of N-terminal protonation on dissociation","volume":"18","author":"Unnithan","year":"2007","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.chroma.2026.467288_bib0053","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/bph.16336","article-title":"Characterisation of cotadutide's dual GLP-1\/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology model","volume":"181","author":"Bosch","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.chroma.2026.467288_bib0054","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), validation of analytical procedures: text and methodology Q2(R1). https:\/\/database.ich.org\/sites\/default\/files\/Q2%28R1%29%20Guideline.pdf (Accessed 27 May 2026)."},{"key":"10.1016\/j.chroma.2026.467288_bib0055","unstructured":"Novo Nordisk Inc., OZEMPIC (semaglutide) injection, for subcutaneous use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/209637s020s021lbl.pdf (Accessed 27 May 2026)."},{"key":"10.1016\/j.chroma.2026.467288_bib0056","unstructured":"Eli Lilly and Company, MOUNJARO (tirzepatide) injection, for subcutaneous use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215866s000lbl.pdf (Accessed 27 May 2026)."}],"container-title":["Journal of Chromatography A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021967326006163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021967326006163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:20:41Z","timestamp":1788783641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021967326006163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":56,"alternative-id":["S0021967326006163"],"URL":"https:\/\/doi.org\/10.1016\/j.chroma.2026.467288","relation":{},"ISSN":["0021-9673"],"issn-type":[{"value":"0021-9673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography A","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chroma.2026.467288","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"467288"}}